Back to today’s briefing

Story perspectives

FDA Approves Dato-DXd: New Hope for Breast Cancer Patients

2/4/2025

26 2

Summary

Story summary

On January 17, 2025, the FDA granted approval for datopotamab deruxtecan (Dato-DXd) as a groundbreaking treatment for adults battling hormone receptor-positive, HER2-negative metastatic breast cancer after previous therapies. The TROPION-Breast01 trial revealed a promising median progression-free survival of 6.9 months, surpassing standard chemotherapy while minimizing severe side effects, bringing hope to many.

1 of 1

Story summary

On January 17, 2025, the FDA granted approval for datopotamab deruxtecan (Dato-DXd) as a groundbreaking treatment for adults battling hormone receptor-positive, HER2-negative metastatic breast cancer after previous therapies. The TROPION-Breast01 trial revealed a promising median progression-free survival of 6.9 months, surpassing standard chemotherapy while minimizing severe side effects, bringing hope to many.